Drug Trial Radar · NCT02720367
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jan 2016
Primary completion
Jan 2018
Study completion Mar 2020
Sponsor
- Lead sponsor
- Taris Biomedical LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)
Conditions
- Urinary Bladder Cancer
Interventions
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Drug
TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as defined by the number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0Time frame: From the point of signing the informed consent form through last study visit, up to 59 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Radboudumc
Nijmegen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.